Roche Holding AG Pharma Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matthew Weston - UBS Investment Bank - Analyst : Thank you. Good morning. It's Matthew Weston from UBS. Two questions if I can please. One on commercialization, which I know is some way away for elements of the pipeline and also one about portfolio prioritization. So on commercialization, Roche has been very much a specialty care business, but you're now moving forward in some extremely competitive categories, particularly in cardiometabolic and in inflammation. Teresa, I'd love to understand how you're looking to change the commercial organization in particularly how you're going to tackle some of the very significant managed care barriers that some of the existing entrenched competitors will have when you come to market with your assets. And then secondly, Levi on your applying the bar to your portfolio, I assume all of your phase 3 assets, you just decided that there was no way you could terminate development of those pipeline potential going forward because they were too established. I'd love to know, did you apply the bar to your current phase 3 assets? And if so did any of them not pass?

Question: Matthew Weston - UBS Investment Bank - Analyst : I think what I heard a lot about one quick follow up about the commercialization strategy is differentiation when it comes to managed care barriers. So is that something we should hold you to account and particularly in obesity, as we see you develop your portfolio that we have to see differentiation for you to feel that you can address those managed care barriers when you come to market.